Commissioner Succession Plan? Abernethy As Gottlieb’s Number Two Offers One Option

Gottlieb’s choice of Amy Abernethy as US FDA principal deputy could set her up to succeed him, should the need arise. CDER’s Cavazzoni will fill the post on temporary basis, elevating her profile within agency.

FDAEntrance_1200x675

US FDA Commissioner Scott Gottlieb’s choice of Flatiron Health Inc. executive Amy Abernethy as his principal deputy commissioner to success a retiring Rachel Sherman offers one potential succession plan, should he decide to eventually leave the agency.

In Abernethy, Gottlieb brings to FDA an individual whose background neatly overlaps with much of the agency’s leadership over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership